Q2 EPS Forecast for iTeos Therapeutics Increased by Analyst

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Equities research analysts at HC Wainwright increased their Q2 2025 earnings estimates for iTeos Therapeutics in a research report issued to clients and investors on Tuesday, April 29th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($1.17) per share for the quarter, up from their previous forecast of ($1.44). HC Wainwright has a “Buy” rating and a $46.00 price target on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for iTeos Therapeutics’ Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($1.46) EPS, FY2025 earnings at ($4.89) EPS, FY2026 earnings at ($5.44) EPS, FY2027 earnings at ($3.31) EPS and FY2028 earnings at ($0.70) EPS.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.14.

Other analysts have also issued research reports about the company. Wells Fargo & Company cut their price objective on iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Tuesday. Wedbush reissued an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, March 6th.

iTeos Therapeutics Price Performance

ITOS opened at $7.77 on Friday. The business has a 50 day moving average price of $6.59 and a two-hundred day moving average price of $7.54. The company has a market capitalization of $296.77 million, a price-to-earnings ratio of -2.47 and a beta of 1.43. iTeos Therapeutics has a 1-year low of $4.80 and a 1-year high of $18.75.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC increased its stake in iTeos Therapeutics by 428.7% in the 1st quarter. CWM LLC now owns 8,554 shares of the company’s stock worth $51,000 after purchasing an additional 6,936 shares in the last quarter. Peapod Lane Capital LLC increased its position in shares of iTeos Therapeutics by 24.6% in the first quarter. Peapod Lane Capital LLC now owns 135,655 shares of the company’s stock worth $810,000 after acquiring an additional 26,802 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of iTeos Therapeutics by 25.1% during the first quarter. Exchange Traded Concepts LLC now owns 17,308 shares of the company’s stock valued at $103,000 after acquiring an additional 3,468 shares during the period. Wellington Management Group LLP lifted its position in shares of iTeos Therapeutics by 4.3% in the 4th quarter. Wellington Management Group LLP now owns 110,332 shares of the company’s stock valued at $847,000 after acquiring an additional 4,563 shares in the last quarter. Finally, Public Employees Retirement System of Ohio boosted its stake in iTeos Therapeutics by 192.2% in the 4th quarter. Public Employees Retirement System of Ohio now owns 84,220 shares of the company’s stock worth $647,000 after purchasing an additional 55,394 shares during the period. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.